CD274 and head and neck cancer: Immune checkpoint inhibition with monoclonal antibodies against cytotoxic T lymphocyte antigen‐4 and PD‐1/PD‐L1 by combination treatments became another new option in head and neck cancer.36 The ongoing EAGLE study is comparing the efficacy and safety of durvalumab as monotherapy or in combination with tremelimumab to standard‐of‐care in head and neck cancer.37